American Century Companies
CMPX icon

American Century Companies’s Compass Therapeutics CMPX Stock Holding History

American Century Companies’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-78,328
Closed -$414K – 2904
2026
Q1 		$414K Buy
78,328
+37,916
+94% +$219K ﹤0.01% 2564
2025
Q4 		$217K Buy
+40,412
New +$187K ﹤0.01% 2695
2025
Q3 		– Sell
-27,607
Closed -$71.8K – 2803
2025
Q2 		$71.8K Sell
27,607
-46,075
-63% -$95K ﹤0.01% 2814
2025
Q1 		$140K Buy
+73,682
New +$196K ﹤0.01% 2801

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

American Century Companies's CMPX Position: Q2 2026 in Review

American Century Companies sold out of Compass Therapeutics (CMPX) in Q2 2026, closing a stake of 78,328 shares — an estimated $414K sold.

American Century Companies first reported a position in CMPX in Q1 2025 and held it in 4 quarters. The position peaked at $414K in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • American Century Companies reported no remaining Compass Therapeutics position as of Q2 2026 after selling out during the quarter.
  • American Century Companies sold 78,328 Compass Therapeutics shares in Q2 2026, an estimated $414K.
  • American Century Companies first reported a position in Compass Therapeutics in Q1 2025 and held it in 4 quarters.
  • American Century Companies's Compass Therapeutics position peaked at $414K in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.